Hepatic steatosis after pediatric liver transplant

Emily R. Perito, Tabitha Vase, Rageshree Ramachandran, Andrew Phelps, Kuang‐Yu Jen, Robert H. Lustig, Vickie A. Feldstein, Philip Rosenthal – 20 April 2017 – Hepatic steatosis develops after liver transplantation (LT) in 30% of adults, and nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in nontransplanted children. However, posttransplant steatosis has been minimally studied in pediatric LT recipients. We explored the prevalence, persistence, and association with chronic liver damage of hepatic steatosis in these children.

A simplified multivisceral transplantation procedure for patients with combined end‐stage liver disease and type 2 diabetes mellitus

Xiao‐Shun He, Shun‐Jun Fu, Qiang Zhao, Xiao‐Feng Zhu, Dong‐Ping Wang, Ming Han, Wei‐Qiang Ju, Yi Ma, Xing‐Yuan Jiao, Xiao‐Peng Yuan, An‐Bin Hu, Zhi‐Yong Guo – 19 April 2017 – In liver transplant patients with type 2 diabetes mellitus (DM), the disease worsens after transplantation because of longterm use of diabetogenic immunosuppressive drugs, making management of those patients a great challenge.

Pentraxin‐3 modulates lipopolysaccharide‐induced inflammatory response and attenuates liver injury

Luis Perea, Mar Coll, Lucia Sanjurjo, Delia Blaya, Adil El Taghdouini, Daniel Rodrigo‐Torres, José Altamirano, Isabel Graupera, Beatriz Aguilar‐Bravo, Marta Llopis, Julia Vallverdú, Joan Caballeria, Leo A. van Grunsven, Maria‐Rosa Sarrias, Pere Ginès, Pau Sancho‐Bru – 19 April 2017 – Acute‐on‐chronic liver injury is characterized by an important inflammatory response frequently associated with endotoxemia. In this context, acute‐phase proteins such as Pentraxin‐3 (PTX3) are released; however, little is known about their role in chronic liver disease.

Subscribe to